Immune globulin 20% (Grifols)

N/A

Report date: 2026/04/21 20:00:18

Base Information

Drug NameImmune globulin 20% (Grifols)
Drug Alias NameImmune Globulin Subcutaneous, Human-klhw, 20% (Grifols)XEMBIFYC19-IG
ClassificationBiologics > Blood components
Mechanisms of ActionImmunostimulants
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Primary Immunodeficiency DiseasesAgammaglobulinemia +[8] 
Global Approved IndicationsPrimary Immunodeficiency Diseases
Approved Indications in ChinaN/A
Original Approved Country/TerritoryUnited States
Original Approved Date2019/07/03
Country/TerritoryBosnia and HerzegovinaBulgariaUnited States +[9] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesGrifols Therapeutics Llc
China Registration ClassN/A

Develop Information

Active CompaniesGrifols Therapeutics Llc
Inactive CompaniesN/A
Active IndicationsPrimary Immunodeficiency DiseasesAgammaglobulinemiaPolyradiculoneuropathy, Chronic Inflammatory Demyelinating +[7] 
Inactive IndicationsCoronavirus Disease 2019 (COVID-19)

Other Information

ATC CodeJ06BA
Related LinksN/A